Panbela Therapeutics Inc
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal ad… Read more
Panbela Therapeutics Inc (PBLA) - Total Liabilities
Latest total liabilities as of September 2024: $23.34 Million USD
Based on the latest financial reports, Panbela Therapeutics Inc (PBLA) has total liabilities worth $23.34 Million USD as of September 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Panbela Therapeutics Inc - Total Liabilities Trend (2011–2023)
This chart illustrates how Panbela Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Panbela Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Panbela Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
NICE CALL PUBLIC COMPANY LIMITED
BK:NCP
|
Thailand | ฿29.12 Million |
|
MARKETAXESS HOLDING
MU:MWI
|
Germany | €446.80 Million |
|
Instituto Rosenbusch S.A.
BA:ROSE
|
Argentina | AR$7.45 Billion |
|
Dalrada Financial Corp
PINK:DFCO
|
USA | $30.58 Million |
|
Gossan Resources Ltd
V:GSS
|
Canada | CA$139.75K |
|
Agentix Corp
PINK:AGTX
|
USA | $3.50 Million |
|
Intra Energy Corporation
AU:IEC
|
Australia | AU$1.12 Million |
Liability Composition Analysis (2011–2023)
This chart breaks down Panbela Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.26 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 4.52 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Panbela Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Panbela Therapeutics Inc (2011–2023)
The table below shows the annual total liabilities of Panbela Therapeutics Inc from 2011 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $16.51 Million | +26.75% |
| 2022-12-31 | $13.03 Million | +389.74% |
| 2021-12-31 | $2.66 Million | +94.87% |
| 2020-12-31 | $1.36 Million | -22.40% |
| 2019-12-31 | $1.76 Million | +7.91% |
| 2018-12-31 | $1.63 Million | -63.42% |
| 2017-12-31 | $4.46 Million | -19.26% |
| 2016-12-31 | $5.52 Million | +22.94% |
| 2015-12-31 | $4.49 Million | +626.29% |
| 2014-12-31 | $618.08K | -7.77% |
| 2013-12-31 | $670.15K | +2.82% |
| 2012-12-31 | $651.75K | -1.07% |
| 2011-12-31 | $658.78K | -- |